Top

Current Treatment Options in Oncology

Published in:

01-04-2007 | Chronic Leukemia

Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia

Authors: Naomi Galili, Ph.D., Jan Cerny, M.D., Azra Raza, M.D.

Published in: Current Treatment Options in Oncology | Issue 2/2007

Title: Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia
Authors: Naomi Galili, Ph.D.
Jan Cerny, M.D.
Azra Raza, M.D.
Publication date: 01-04-2007
Publisher: Current Science Inc.
Published in: Current Treatment Options in Oncology / Issue 2/2007
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-007-0017-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2007

Outline for Writing an Article for Current Treatment Options in Oncology: Splenic Lymphoma with Villous Lymphocytes

Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation

Splenic marginal zone lymphoma with and without villous lymphocytes

Hairy Cell Leukemia

Treatment of Waldenstrom’s Macroglobulinemia

Lenalidomide in Myeloma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer